Literature DB >> 3117538

Comparative in vitro activity of RO 23-6240 (fleroxacin), a new 4-quinolone derivative.

K Machka1, I Braveny.   

Abstract

The in vitro activity of RO 23-6240 was compared with that of norfloxacin, ofloxacin and ciprofloxacin as well as four other antimicrobial agents against 345 recent clinical isolates. The MICs of RO 23-6240 against Enterobacteriaceae and Acinetobacter anitratum was less than or equal to 0.5 mg/l. At the same concentration of the compound 90% of staphylococci were inhibited. Against Enterococcus faecalis and Pseudomonas aeruginosa RO 23-6240 proved less active, having MIC90 values of 4.0 mg/l and 8.0 mg/l, respectively. Enterobacteriaceae and staphylococci strains that were resistant to piperacillin, cefotaxime or tobramycin were susceptible to the compound. In general the activity of RO 23-6240 was comparable to those of norfloxacin and ofloxacin, but less than that of ciprofloxacin.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3117538     DOI: 10.1007/bf02013116

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN: 0722-2211            Impact factor:   3.267


  5 in total

1.  In vitro activity of Ro 23-6240, a new difluoroquinolone derivative, compared with that of other antimicrobial agents.

Authors:  N Manek; J M Andrews; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

2.  In vitro activity of the new 4-quinolone compound Ro 23-6240.

Authors:  A M Clarke; S J Zemcov
Journal:  Eur J Clin Microbiol       Date:  1987-04       Impact factor: 3.267

3.  In vitro activity of Ro 23-6240, a new fluorinated 4-quinolone.

Authors:  N X Chin; D C Brittain; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1986-04       Impact factor: 5.191

4.  Evaluation of the Micur microdilution systems for antibiotic susceptibility testing of gram-negative and gram-positive bacteria.

Authors:  F Kayser; K Machka; L Wieczorek; D Banauch; W Bablok; I Braveny
Journal:  Eur J Clin Microbiol       Date:  1982-12       Impact factor: 3.267

5.  In vitro and in vivo antibacterial activity of AM-833, a new quinolone derivative.

Authors:  K Hirai; H Aoyama; M Hosaka; Y Oomori; Y Niwata; S Suzue; T Irikura
Journal:  Antimicrob Agents Chemother       Date:  1986-06       Impact factor: 5.191

  5 in total
  6 in total

Review 1.  Fleroxacin clinical pharmacokinetics.

Authors:  A E Stuck; D K Kim; F J Frey
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

2.  Activity of fleroxacin alone and in combination with clindamycin or metronidazole in experimental intra-abdominal abscesses.

Authors:  A Pefanis; C Thauvin-Eliopoulos; J Holden; G M Eliopoulos; M J Ferraro; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

3.  Pharmacokinetics of [18F]fleroxacin in patients with acute exacerbations of chronic bronchitis and complicated urinary tract infection studied by positron emission tomography.

Authors:  A J Fischman; E Livni; J W Babich; N M Alpert; A Bonab; S Chodosh; F McGovern; P Kamitsuka; Y Y Liu; R Cleeland; B L Prosser; J A Correia; R H Rubin
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

4.  Pharmacokinetics of [18F]fleroxacin in healthy human subjects studied by using positron emission tomography.

Authors:  A J Fischman; E Livni; J Babich; N M Alpert; Y Y Liu; E Thom; R Cleeland; B L Prosser; J A Correia; H W Strauss
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

Review 5.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132

Review 6.  Developments in quinolones. Bacteriology, pharmacokinetics and initial clinical experience of several investigational quinolone derivatives.

Authors:  R Janknegt; Y A Hekster
Journal:  Pharm Weekbl Sci       Date:  1989-04-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.